Identification

Name
Dapiprazole
Accession Number
DB00298  (APRD00902)
Type
Small Molecule
Groups
Approved
Description

Dapiprazole (U.S. trade name Rev-Eyes) is an alpha blocker. It is used to reverse mydriasis after eye examination. [Wikipedia]

Structure
Thumb
Synonyms
  • 5,6,7,8-Tetrahydro-3-(2-(4-(O-tolyl)-1-piperazinyl)ethyl)-S-triazolo(4,3-a)pyridine
  • Dapiprazol
  • Dapiprazolum
Product Ingredients
IngredientUNIICASInChI Key
Dapiprazole hydrochlorideDS9UJN1I0X72822-13-0ZIODNPFQZIHCOE-UHFFFAOYSA-N
International/Other Brands
Rev-Eyes
Categories
UNII
5RNZ8GJO7K
CAS number
72822-12-9
Weight
Average: 325.4512
Monoisotopic: 325.226645889
Chemical Formula
C19H27N5
InChI Key
RFWZESUMWJKKRN-UHFFFAOYSA-N
InChI
InChI=1S/C19H27N5/c1-16-6-2-3-7-17(16)23-14-12-22(13-15-23)11-9-19-21-20-18-8-4-5-10-24(18)19/h2-3,6-7H,4-5,8-15H2,1H3
IUPAC Name
1-(2-methylphenyl)-4-(2-{5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyridin-3-yl}ethyl)piperazine
SMILES
CC1=CC=CC=C1N1CCN(CCC2=NN=C3CCCCN23)CC1

Pharmacology

Indication

Used in the treatment of iatrogenically induced mydriasis produced by adrenergic (phenylephrine) or parasympatholytic (tropicamide) agents used in certain eye examinations.

Pharmacodynamics

Dapiprazole is an alpha-adrenergic blocking agent. It produces miosis by blocking the alpha-adrenergic receptors on the dilator muscle of the iris. Dapiprazole produces no significant action on ciliary muscle contraction and thus, there are no changes in the depth of the anterior chamber of the thickness of the lens. It does not alter the IOP either in normal eyes or in eyes with elevated IOP. The rate of pupillary constriction may be slightly slower in clients with brown irises than in clients with blue or green irises.

Mechanism of action

Dapiprazole acts through blocking the alpha1-adrenergic receptors in smooth muscle. It produces miosis through an effect on the dilator muscle of the iris and does not have any significant activity on ciliary muscle contraction and, therefore does not induce a significant change in the anterior chamber depth or the thickness of the lens.

TargetActionsOrganism
AAlpha-1A adrenergic receptor
antagonist
Human
AAlpha-1D adrenergic receptor
antagonist
Human
AAlpha-1B adrenergic receptor
antagonist
Human
Absorption

Systemic absorption is negligible.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Oral LD50 is 1189-2100 mg/kg in mice, rats and rabbits.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineDapiprazole may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineDapiprazole may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineDapiprazole may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineDapiprazole may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineDapiprazole may decrease the vasoconstricting activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with 7-Nitroindazole.Experimental
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved, Investigational
AcepromazineDapiprazole may increase the antihypertensive activities of Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Adipiplon.Investigational
AdrafinilDapiprazole may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineDapiprazole may decrease the vasoconstricting activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Dapiprazole.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Dapiprazole.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Dapiprazole.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dapiprazole.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved, Withdrawn
AmibegronDapiprazole may decrease the vasoconstricting activities of Amibegron.Investigational
AmiodaroneAmiodarone may increase the orthostatic hypotensive activities of Dapiprazole.Approved, Investigational
AmisulprideDapiprazole may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitrazDapiprazole may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineDapiprazole may increase the antihypertensive activities of Amitriptyline.Approved
AmlodipineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dapiprazole.Approved, Illicit
AmoxapineDapiprazole may increase the antihypertensive activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Amperozide.Experimental
AmphetamineDapiprazole may decrease the stimulatory activities of Amphetamine.Approved, Illicit, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Dapiprazole is combined with Amrinone.Approved
AnisodamineDapiprazole may decrease the vasoconstricting activities of Anisodamine.Investigational
ApomorphineDapiprazole may decrease the vasoconstricting activities of Apomorphine.Approved, Investigational
ApraclonidineDapiprazole may decrease the vasoconstricting activities of Apraclonidine.Approved
AranidipineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Aranidipine.Approved, Investigational
ArbutamineDapiprazole may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolDapiprazole may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleDapiprazole may increase the antihypertensive activities of Aripiprazole.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Dapiprazole.Investigational
ArticaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Articaine.Approved
AsenapineDapiprazole may increase the antihypertensive activities of Asenapine.Approved
AtenololAtenolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved
AvanafilAvanafil may increase the hypotensive activities of Dapiprazole.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Azaperone.Investigational, Vet Approved
AzelastineDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Dapiprazole is combined with Azimilide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Dapiprazole.Approved
BambuterolDapiprazole may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarbitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Barbital.Illicit
BarnidipineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Dapiprazole.Experimental
BencyclaneThe risk or severity of hypotension can be increased when Dapiprazole is combined with Bencyclane.Experimental
BenidipineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Benidipine.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Benzocaine.Approved, Investigational
BenzphetamineDapiprazole may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Benzyl alcohol.Approved
BepridilThe risk or severity of hypotension can be increased when Dapiprazole is combined with Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved, Investigational
BevantololDapiprazole may increase the antihypertensive activities of Bevantolol.Approved
BioallethrinThe risk or severity of hypotension can be increased when Dapiprazole is combined with Bioallethrin.Approved, Experimental
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved
BitolterolDapiprazole may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved
BrexpiprazoleDapiprazole may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dapiprazole.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dapiprazole.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Dapiprazole.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololBucindolol may increase the antihypertensive activities of Dapiprazole.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Dapiprazole.Experimental, Investigational
BunazosinBunazosin may increase the antihypertensive activities of Dapiprazole.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dapiprazole.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved
BuprenorphineDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dapiprazole.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dapiprazole.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Dapiprazole.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dapiprazole.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Dapiprazole.Approved
CanertinibThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dapiprazole.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Dapiprazole.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Carboxyamidotriazole.Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dapiprazole.Approved
CaroverineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Caroverine.Experimental
CarteololCarteolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Dapiprazole.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dapiprazole.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dapiprazole.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dapiprazole.Approved
ChlorphentermineDapiprazole may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineDapiprazole may increase the antihypertensive activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dapiprazole.Approved
CilnidipineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Cilnidipine.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Cinnarizine.Approved, Investigational
CirazolineDapiprazole may decrease the vasoconstricting activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Dapiprazole.Approved, Investigational
ClenbuterolDapiprazole may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Clevidipine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Dapiprazole.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Dapiprazole.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dapiprazole.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Dapiprazole.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dapiprazole.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clopenthixol.Experimental
CloranololCloranolol may increase the orthostatic hypotensive activities of Dapiprazole.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dapiprazole.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clothiapine.Experimental
ClozapineDapiprazole may increase the antihypertensive activities of Clozapine.Approved
CocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dapiprazole.Approved, Illicit
CyclandelateThe risk or severity of hypotension can be increased when Dapiprazole is combined with Cyclandelate.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Dapiprazole.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dapiprazole.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cyclopropane.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Dapiprazole.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Dapiprazole.Approved, Investigational
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Dapiprazole.Investigational
DarodipineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Darodipine.Experimental
DeramciclaneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dapiprazole.Approved
DesipramineDesipramine may increase the orthostatic hypotensive activities of Dapiprazole.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dapiprazole.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dapiprazole.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDapiprazole may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Dapiprazole.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Dapiprazole.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Diethyl ether.Experimental
DiethylpropionDapiprazole may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Dapiprazole.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dapiprazole.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dapiprazole.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe risk or severity of hypotension can be increased when Dapiprazole is combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dapiprazole.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dapiprazole.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dapiprazole.Approved, Illicit
DipivefrinDapiprazole may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Dapiprazole.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dixyrazine.Experimental
DL-MethylephedrineDapiprazole may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutamineDapiprazole may decrease the vasoconstricting activities of Dobutamine.Approved
DopexamineDapiprazole may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DoramectinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Doramectin.Vet Approved
DotarizineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Dapiprazole.Approved
DoxepinDapiprazole may increase the antihypertensive activities of Doxepin.Approved, Investigational
DoxofyllineDapiprazole may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Dapiprazole is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved, Illicit
DronedaroneDapiprazole may increase the antihypertensive activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Drotebanol.Experimental, Illicit
DroxidopaDapiprazole may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Dapiprazole.Approved, Investigational
EfonidipineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Efonidipine.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Dapiprazole.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dapiprazole.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Dapiprazole.Approved, Investigational
EpanololEpanolol may increase the orthostatic hypotensive activities of Dapiprazole.Experimental
EperisoneThe risk or severity of hypotension can be increased when Dapiprazole is combined with Eperisone.Approved, Investigational
EphedraDapiprazole may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineDapiprazole may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineDapiprazole may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineDapiprazole may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Dapiprazole.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Dapiprazole.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Dapiprazole.Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Dapiprazole.Experimental
EscitalopramDapiprazole may increase the antihypertensive activities of Escitalopram.Approved, Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Dapiprazole.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dapiprazole.Approved, Investigational
EtafedrineDapiprazole may decrease the vasoconstricting activities of Etafedrine.Approved
EthanolDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dapiprazole.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dapiprazole.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dapiprazole.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Etifoxine.Investigational, Withdrawn
EtilefrineDapiprazole may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dapiprazole.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Dapiprazole.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Dapiprazole.Approved
FelodipineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Fendiline.Withdrawn
FenoterolDapiprazole may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dapiprazole.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Dapiprazole.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Dapiprazole is combined with Fish oil.Approved, Nutraceutical
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Dapiprazole.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Dapiprazole.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluoxetine.Approved, Vet Approved
FlupentixolDapiprazole may increase the antihypertensive activities of Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dapiprazole.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dapiprazole.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Dapiprazole.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dapiprazole.Approved, Investigational
FormoterolDapiprazole may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Dapiprazole.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fospropofol.Approved, Illicit, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Dapiprazole.Approved, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Dapiprazole.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dapiprazole.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Dapiprazole.Approved, Investigational
GallopamilThe risk or severity of hypotension can be increased when Dapiprazole is combined with Gallopamil.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dapiprazole.Approved, Illicit, Investigational
GepefrineDapiprazole may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Glutethimide.Approved, Illicit
GuanabenzDapiprazole may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dapiprazole.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dapiprazole.Approved
HalothaneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Hexobarbital.Approved
HexoprenalineDapiprazole may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineDapiprazole may decrease the vasoconstricting activities of Higenamine.Investigational
HydrocodoneDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dapiprazole.Approved, Illicit
HydroxyamphetamineDapiprazole may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
IloperidoneDapiprazole may increase the antihypertensive activities of Iloperidone.Approved
ImipramineDapiprazole may increase the antihypertensive activities of Imipramine.Approved
IndacaterolDapiprazole may decrease the vasoconstricting activities of Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Indalpine.Investigational, Withdrawn
IndenololIndenolol may increase the orthostatic hypotensive activities of Dapiprazole.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Indiplon.Investigational
IndoraminIndoramin may increase the antihypertensive activities of Dapiprazole.Withdrawn
Iofetamine I-123Dapiprazole may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Dapiprazole.Approved
IsoetarineDapiprazole may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dapiprazole.Approved, Vet Approved
IsomethepteneDapiprazole may decrease the vasoconstricting activities of Isometheptene.Approved
IsoprenalineDapiprazole may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
IsoxsuprineDapiprazole may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Isradipine.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dapiprazole.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ketobemidone.Approved, Investigational
LabetalolLabetalol may increase the antihypertensive activities of Dapiprazole.Approved
LacidipineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dapiprazole.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Dapiprazole.Investigational
LercanidipineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Dapiprazole.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Dapiprazole.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Dapiprazole.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dapiprazole.Approved
LevosalbutamolDapiprazole may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dapiprazole.Approved, Vet Approved
LidoflazineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Lidoflazine.Experimental
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Dapiprazole.Approved, Investigational
LisdexamfetamineDapiprazole may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
Lithium cationLithium may increase the neurotoxic activities of Dapiprazole.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Dapiprazole can be increased when used in combination with Lofexidine.Approved, Investigational
LoperamideThe risk or severity of hypotension can be increased when Dapiprazole is combined with Loperamide.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Dapiprazole.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dapiprazole.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Dapiprazole.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dapiprazole.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dapiprazole.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Dapiprazole can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Dapiprazole.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Dapiprazole.Approved
MedazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Melperone.Approved, Investigational
MentholThe risk or severity of hypotension can be increased when Dapiprazole is combined with Menthol.Approved
MephedroneDapiprazole may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineDapiprazole may decrease the stimulatory activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Dapiprazole.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dapiprazole.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Meptazinol.Experimental
MequitazineDapiprazole may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Mesoridazine.Approved, Investigational
MetaraminolDapiprazole may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dapiprazole.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dapiprazole.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineDapiprazole may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dapiprazole.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dapiprazole.Approved
MethotrimeprazineDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxamineDapiprazole may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineDapiprazole may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dapiprazole.Approved
MethyldopaDapiprazole may decrease the vasoconstricting activities of Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Dapiprazole.Approved, Investigational
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved, Investigational
MetyrosineDapiprazole may increase the sedative activities of Metyrosine.Approved
MibefradilThe risk or severity of hypotension can be increased when Dapiprazole is combined with Mibefradil.Investigational, Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Dapiprazole.Approved, Illicit
MidodrineDapiprazole may decrease the vasoconstricting activities of Midodrine.Approved
MidomafetamineDapiprazole may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved, Investigational
MirabegronDapiprazole may decrease the vasoconstricting activities of Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Dapiprazole.Investigational
MirtazapineDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDADapiprazole may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Dapiprazole.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dapiprazole.Approved, Investigational
MoxonidineDapiprazole may decrease the vasoconstricting activities of Moxonidine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved
NaftopidilThe risk or severity of hypotension can be increased when Dapiprazole is combined with Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dapiprazole.Approved
NaphazolineDapiprazole may decrease the vasoconstricting activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Dapiprazole.Approved, Investigational
NebivololNebivolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved, Investigational
NefazodoneDapiprazole may increase the antihypertensive activities of Nefazodone.Approved, Withdrawn
NicardipineDapiprazole may increase the antihypertensive activities of Nicardipine.Approved, Investigational
NicergolineDapiprazole may increase the antihypertensive activities of Nicergoline.Approved, Investigational
NifedipineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Nifedipine.Approved
NiguldipineDapiprazole may increase the antihypertensive activities of Niguldipine.Experimental
NiludipineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Dapiprazole is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dapiprazole.Approved
NitrendipineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Nitrendipine.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Dapiprazole.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Nordazepam.Approved
NorepinephrineDapiprazole may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineDapiprazole may decrease the vasoconstricting activities of Norfenefrine.Experimental
NorfluraneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Normethadone.Approved, Illicit
NortriptylineDapiprazole may increase the antihypertensive activities of Nortriptyline.Approved
NylidrinDapiprazole may decrease the vasoconstricting activities of Nylidrin.Approved
OctopamineDapiprazole may decrease the vasoconstricting activities of Octopamine.Experimental
OlanzapineDapiprazole may increase the antihypertensive activities of Olanzapine.Approved, Investigational
OlodaterolDapiprazole may decrease the vasoconstricting activities of Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dapiprazole.Approved
OndansetronThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Opium.Approved, Illicit
OrciprenalineDapiprazole may decrease the vasoconstricting activities of Orciprenaline.Approved
OrphenadrineDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Osanetant.Investigational
OtiloniumThe risk or severity of hypotension can be increased when Dapiprazole is combined with Otilonium.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dapiprazole.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dapiprazole.Approved, Illicit, Investigational
OxyfedrineDapiprazole may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineDapiprazole may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dapiprazole.Approved, Investigational, Vet Approved
PaliperidoneDapiprazole may increase the antihypertensive activities of Paliperidone.Approved
ParaldehydeDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Paroxetine.Approved, Investigational
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dapiprazole.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dapiprazole.Approved, Investigational, Vet Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Dapiprazole.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
PerazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Perazine.Approved, Investigational
PergolideDapiprazole may decrease the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dapiprazole.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dapiprazole.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Phenazocine.Experimental
PhendimetrazineDapiprazole may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Dapiprazole.Approved
PhenibutThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dapiprazole.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Phenoperidine.Experimental
PhenoxybenzamineDapiprazole may increase the antihypertensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Phenoxyethanol.Approved
PhentermineDapiprazole may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolamineDapiprazole may increase the antihypertensive activities of Phentolamine.Approved
PhenylephrineDapiprazole may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineDapiprazole may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Dapiprazole.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Dapiprazole.Approved
PinaveriumThe risk or severity of hypotension can be increased when Dapiprazole is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Dapiprazole.Approved, Investigational
PirbuterolDapiprazole may decrease the vasoconstricting activities of Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Piritramide.Approved, Investigational
PizotifenDapiprazole may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Dapiprazole.Experimental
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Dapiprazole.Approved
PractololPractolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved
PramipexoleDapiprazole may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Prazepam.Approved, Illicit
PrazosinPrazosin may increase the antihypertensive activities of Dapiprazole.Approved
PregabalinThe therapeutic efficacy of Dapiprazole can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenalterolDapiprazole may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Prenylamine.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Dapiprazole.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Dapiprazole.Approved, Investigational
ProcaterolDapiprazole may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dapiprazole.Approved, Vet Approved
PromazineDapiprazole may increase the antihypertensive activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Dapiprazole.Approved, Investigational
PropafenonePropafenone may increase the orthostatic hypotensive activities of Dapiprazole.Approved
PropanididThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Proparacaine.Approved, Vet Approved
PropericiazineDapiprazole may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazineDapiprazole may increase the antihypertensive activities of Propiomazine.Approved
PropiverineDapiprazole may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dapiprazole.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Propoxycaine.Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved, Investigational
ProtokylolDapiprazole may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dapiprazole.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Dapiprazole is combined with PSD502.Investigational
PseudoephedrineDapiprazole may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Dapiprazole.Approved, Illicit
QuetiapineDapiprazole may increase the antihypertensive activities of Quetiapine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Dapiprazole.Approved, Investigational
QuinidineDapiprazole may increase the antihypertensive activities of Quinidine.Approved, Investigational
QuinisocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Quinisocaine.Experimental
RacepinephrineDapiprazole may increase the antihypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Raclopride.Investigational
RactopamineDapiprazole may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Dapiprazole.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Dapiprazole.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dapiprazole.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Remoxipride.Approved, Withdrawn
ReproterolDapiprazole may decrease the vasoconstricting activities of Reproterol.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dapiprazole.Approved, Investigational
RilmenidineDapiprazole may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RimiterolDapiprazole may decrease the vasoconstricting activities of Rimiterol.Experimental
RisperidoneDapiprazole may increase the antihypertensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ritanserin.Investigational
RitobegronDapiprazole may decrease the stimulatory activities of Ritobegron.Investigational
RitodrineDapiprazole may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Dapiprazole.Approved
RomifidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Romifidine.Vet Approved
RopiniroleDapiprazole may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dapiprazole.Approved
RotigotineDapiprazole may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dapiprazole.Approved
SalbutamolDapiprazole may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolDapiprazole may decrease the vasoconstricting activities of Salmeterol.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dapiprazole.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dapiprazole.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Dapiprazole.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Dapiprazole is combined with Seletracetam.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dapiprazole.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Dapiprazole.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Dapiprazole.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
SolabegronDapiprazole may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Dapiprazole.Approved
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Dapiprazole.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dapiprazole.Approved, Investigational
SulpirideDapiprazole may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Dapiprazole.Approved, Investigational
SuvorexantDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SynephrineDapiprazole may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Dapiprazole.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Dapiprazole.Investigational
TamsulosinTamsulosin may increase the antihypertensive activities of Dapiprazole.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Dapiprazole.Approved, Investigational
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Dapiprazole.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dapiprazole.Approved, Investigational
TerazosinTerazosin may increase the antihypertensive activities of Dapiprazole.Approved
TerbutalineTerbutaline may increase the orthostatic hypotensive activities of Dapiprazole.Approved
TerodilineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Dapiprazole.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Dapiprazole.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tetrodotoxin.Investigational
TetryzolineDapiprazole may decrease the vasoconstricting activities of Tetryzoline.Approved
ThalidomideDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the hypotensive activities of Dapiprazole.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Thiopental.Approved, Vet Approved
ThioproperazineDapiprazole may increase the antihypertensive activities of Thioproperazine.Approved
ThioridazineDapiprazole may increase the antihypertensive activities of Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dapiprazole.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Dapiprazole.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tilidine.Experimental
TimololTimolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dapiprazole.Approved, Investigational
TolazolineDapiprazole may increase the antihypertensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dapiprazole.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of hypotension can be increased when Dapiprazole is combined with Tolfenamic Acid.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Dapiprazole.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dapiprazole.Approved, Investigational
TranilastThe risk or severity of hypotension can be increased when Dapiprazole is combined with Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tranylcypromine.Approved, Investigational
TrazodoneDapiprazole may increase the antihypertensive activities of Trazodone.Approved, Investigational
TretoquinolDapiprazole may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Dapiprazole.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Trichloroethylene.Approved
TrifluoperazineDapiprazole may increase the antihypertensive activities of Trifluoperazine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Triflupromazine.Approved, Vet Approved
TrimazosinTrimazosin may increase the antihypertensive activities of Dapiprazole.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Dapiprazole is combined with Trimethadione.Approved
TrimipramineDapiprazole may increase the antihypertensive activities of Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Dapiprazole.Approved
TulobuterolDapiprazole may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Dapiprazole.Approved, Investigational
UrapidilUrapidil may increase the antihypertensive activities of Dapiprazole.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Valproic Acid.Approved, Investigational
VardenafilVardenafil may increase the hypotensive activities of Dapiprazole.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dapiprazole.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Veralipride.Experimental
VerapamilDapiprazole may increase the antihypertensive activities of Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Dapiprazole.Approved
VilanterolDapiprazole may decrease the vasoconstricting activities of Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Dapiprazole.Approved
VinpocetineThe risk or severity of hypotension can be increased when Dapiprazole is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Vortioxetine.Approved, Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Dapiprazole is combined with WIN 55212-2.Experimental
XamoterolDapiprazole may decrease the vasoconstricting activities of Xamoterol.Experimental
XenonThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Xylazine.Vet Approved
XylometazolineDapiprazole may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dapiprazole.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Dapiprazole.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the antihypertensive activities of Dapiprazole.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Dapiprazole.Approved, Investigational
ZolpidemDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dapiprazole.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Dapiprazole.Approved
ZotepineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolDapiprazole may increase the antihypertensive activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0014443
PubChem Compound
3033538
PubChem Substance
46508859
ChemSpider
2298190
ChEBI
51066
ChEMBL
CHEMBL1201216
Therapeutic Targets Database
DAP000298
PharmGKB
PA164749109
Drugs.com
Drugs.com Drug Page
Wikipedia
Dapiprazole
ATC Codes
S01EX02 — Dapiprazole
MSDS
Download (114 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Angelini pharmaceuticals inc
Packagers
  • American Cyanamid Co.
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
logP2.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.751 mg/mLALOGPS
logP2.78ALOGPS
logP2.42ChemAxon
logS-2.6ALOGPS
pKa (Strongest Basic)7.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area37.19 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity100.22 m3·mol-1ChemAxon
Polarizability38.23 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9832
Caco-2 permeable+0.5899
P-glycoprotein substrateSubstrate0.657
P-glycoprotein inhibitor IInhibitor0.8074
P-glycoprotein inhibitor IIInhibitor0.9107
Renal organic cation transporterInhibitor0.7481
CYP450 2C9 substrateNon-substrate0.8296
CYP450 2D6 substrateNon-substrate0.5563
CYP450 3A4 substrateSubstrate0.5833
CYP450 1A2 substrateInhibitor0.6905
CYP450 2C9 inhibitorNon-inhibitor0.5324
CYP450 2D6 inhibitorNon-inhibitor0.632
CYP450 2C19 inhibitorInhibitor0.7506
CYP450 3A4 inhibitorInhibitor0.7338
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9357
Ames testNon AMES toxic0.6215
CarcinogenicityNon-carcinogens0.8546
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7573 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6592
hERG inhibition (predictor II)Inhibitor0.7292
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Triazolopyridines / Dialkylarylamines / Aniline and substituted anilines / Aminotoluenes / N-alkylpiperazines / Aralkylamines / Pyridines and derivatives / Triazoles / Heteroaromatic compounds
show 4 more
Substituents
Phenylpiperazine / N-arylpiperazine / Triazolopyridine / Tertiary aliphatic/aromatic amine / Dialkylarylamine / Aniline or substituted anilines / Aminotoluene / Aralkylamine / N-alkylpiperazine / Toluene
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
N-arylpiperazine, pyridines, N-alkylpiperazine (CHEBI:51066)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Eltze M: Affinity of the miotic drug, dapiprazole, at alpha 1-adrenoceptor subtypes A, B and D. J Pharm Pharmacol. 1997 Nov;49(11):1091-5. [PubMed:9401944]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on July 02, 2018 20:46